CervoMed Soars 74% During Trading After US Patent Extension to 2042
CervoMed(CRVO.US) 盘中涨 74.57%，现报6.651 美元。公司获得美国专利商标局关于 neflamapimod 用于治疗纯路易体痴呆症的专利许可，保护期延长至 2042 年。该专利针对无显著阿尔茨海默病样 tau 病理的 DLB 患者。Neflamapimod 已完成 2b 期临床试验，3 期试验时间取决于获得合作伙伴关系或额外融资。
Source: US Stock Market Update The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments